TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14754783
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy for insomnia
Study: 14754783
Drug: Supervised withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised withdrawal plus cognitive behavior therapy
Study: 2950148
Drug: Tetracycline 1
Normalized name: tetracycline 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 1 gram/day for 6 months plus topical therapy (benzoyl peroxide)
Study: 2950148
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy (2 mg cyproterone acetate plus 50 micrograms ethinyl estradiol; spironolactone 100 mg twice daily; isotretinoin 1 mg/kg)
Study: 30528676
Drug: PF-04457845 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04457845 (4 mg per day)
Study: 28049937
Drug: Heated water-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heated water-based exercise (HEx) training protocol (callisthenic exercises and walking in a heated pool for 1 h, three times weekly for 12 weeks)
Study: 21080201
Drug: Chemotherapy (vinca
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (vinca alkaloids, taxanes, or platina derivatives)
Study: 19333153
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine 0.5 mg and clonidine 100 microg (CMC)
Study: 19333153
Drug: Preservative free
Normalized name: preservative free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative free morphine 0.5 mg (MOR)
Study: 16697968
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue (GnRH-a) injections during cyclophosphamide therapy
Study: 16697968
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injection of GnRH analogue (GnRH-a) during cyclophosphamide therapy
Study: 8993085
Drug: Venlafaxine (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (maximum dose 225 mg/day)
Study: 30659771
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage regimen and formulations
Study: 18514318
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of overall, inferior, and superior quadrant RNFL thicknesses
Study: 16583592
Drug: Colgate Regular
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate Regular Dental Cream
Study: 1508114
Drug: Intravenous and
Normalized name: immune globulin intravenous and subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and intracoronary therapy with streptokinase
Study: 6389014
Drug: Flupirtine maleate
Normalized name: flupirtine maleate
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine maleate (100 mg, oral doses, up to 4 doses per day for 5 days)
Study: 6389014
Drug: Paracetamol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (1 g, oral doses, up to 4 doses per day for 5 days)
Study: 29287749
Drug: Andecaliximab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Andecaliximab (400 mg) administered every 2 weeks for a total of 3 intravenous infusions.
Study: 29287749
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered every 2 weeks for a total of 3 intravenous infusions.
Study: 22633825
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate, 64 mmol/day
Study: 19341900
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-EVAR treatment)
Study: 17929300
Drug: Ribavirin for
Normalized name: Ribavirin for Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin for 72 hours prior to peginterferon alpha‐2a injection
Study: 17929300
Drug: On treatment
Normalized name: STIX 3 DAY YEAST INFECTION TREATMENT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: On treatment (RRs and SRs)
Study: 10770145
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (50 to 200 mg/d, starting at 25 mg/d)
Study: 8420682
Drug: Three monthly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three monthly cycles of cyclophosphamide and cisplatin
Study: 3552699
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 3 g cephalexin
Study: 3552699
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days of cephalexin 1 g or combined preparation of pivmecillinam-pivampicillin
Study: 2566825
Drug: rIFN-gamma treatment
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma treatment for lesions due to Leishmania braziliensis guyanensis
Study: 2566825
Drug: rIFN-gamma treatment
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma treatment for lesions due to Leishmania tropica
Study: 2566825
Drug: rIFN-gamma treatment
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN-gamma treatment
Study: 31984406
Drug: Micro total
Normalized name: Lipantil Micro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro total analysis system (μTAS) based on electrochemical measurements and dielectrophoretic sorting for screening of NAD(P)‐dependent oxidoreductases; specific details on dosage and duration not available.
Study: 31984406
Drug: Boron-doped diamond
Normalized name: diamond
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boron-doped diamond (BDD) electrode for high-throughput measurement of enzyme activity; specific details on dosage and duration not available.
Study: 28852842
Drug: Combined nutraceutical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nutraceutical supplement (one daily tablet containing phytoestrogens, vitamins, micronutrients, and passion flower herbal medicine) for 6 months
Study: 28852842
Drug: Combined nutraceutical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nutraceutical supplement
Study: 25274038
Drug: PSA screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA screening every 4 years (cut-off 4 ng/ml)
Study: 24144057
Drug: Glycine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine (15 g/day)
Study: 21338741
Drug: Large portion
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large portion size (300 g)
Study: 21338741
Drug: Small portion
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small portion size (150 g)
Study: 19687576
Drug: Interferon-beta monotherapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta monotherapy for < or = 24 weeks
Study: 17005085
Drug: Kaixin Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kaixin Capsule (KXC) in combination with conventional Western medicine
Study: 17005085
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicine (Control)
Study: 15546056
Drug: Acute day
Normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute day hospital treatment (87.7 days)
Study: 15546056
Drug: Conventional inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inpatient treatment (67.8 days)
Study: 8447244
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose lithium
Study: 8447244
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily dose lithium
Study: 3533265
Drug: Nitrendipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (20 mg daily for five weeks)
Study: 3533265
Drug: Clonidine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.25 mg daily for five weeks)
Study: 30567725
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 of IV decitabine on days 1 to 10 for up to 4 10-day cycles followed by monthly 5-day cycles
Study: 27311915
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (KE)
Study: 27311915
Drug: Conventional anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional anaesthetics (high dose midazolam, thiopental and/or propofol)
Study: 25855109
Drug: Home self
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home self administration of vaginal misoprostol (800 mcg)
Study: 25855109
Drug: Hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital administration of vaginal misoprostol (800 mcg)
Study: 25855109
Drug: Home self
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home self administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Study: 25855109
Drug: Hospital administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital administration of vaginal misoprostol (800 mcg) after 2nd dose (400 mcg)
Study: 25855109
Drug: Home self
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home self administration of vaginal misoprostol
Study: 25855109
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of extra dose of misoprostol
Study: 8368548
Drug: Fast injection
Normalized name: Fast Freeze
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fast injection (FI) of isobaric 0.5% bupivacaine (2 mL during 2 to 3 s or approximately 0.75 mL/s)
Study: 8368548
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (SI) of isobaric 0.5% bupivacaine (1 mL/min)
Study: 8368548
Drug: Fast reinjection
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast reinjection (FI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Study: 8368548
Drug: Slow reinjection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow reinjection (SI group) of isobaric 0.5% bupivacaine (10 mg, 2 mL)
Study: 31856840
Drug: Neoadjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a long interval (8-12 weeks)
Study: 31856840
Drug: Neoadjuvant concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy with a short interval (4-7 weeks)
Study: 26961539
Drug: LCZ696 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 50 mg
Study: 20236700
Drug: LCZ696 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200 mg
Study: 26961539
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of LCZ696
Study: 25314578
Drug: Whole-body cryostimulation
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryostimulation (WBC) daily during intensified training (ITWBC)
Study: 21667042
Drug: GS-9450 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9450 (10 mg)
Study: 10843174
Drug: Continued GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued GH therapy (0.018 +/- 0.001 mg/kg day)
Study: 10843174
Drug: Open phase
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open phase GH therapy (0.016 mg/kg x day)
Study: 10843174
Drug: Continued GH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued GH treatment
Study: 6686808
Drug: Liquid antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid antacids (various doses)
Study: 6686808
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with anticholinergic and antacids
Study: 6686808
Drug: Antacids (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids (high dose)
Study: 25477278
Drug: 3D documentation
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3D documentation system using Tumor Therapy Manager (TTM)
Study: 24406481
Drug: Sibutramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine treatment (6-week period)
Study: 24406481
Drug: Long-term sibutramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term sibutramine treatment
Study: 17131132
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Sucralfate and Mucaine)
Study: 8739659
Drug: Pharmacotherapy (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (specifics not detailed, but includes alprazolam for a subgroup of 26 patients)
Study: 2183864
Drug: Extradural pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extradural pethidine 50 mg
Study: 2183864
Drug: i.m. pethidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. pethidine 100 mg
Study: 26295650
Drug: Low-dose (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose (260 mAs)
Study: 24586897
Drug: Treatment Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Plus Automated Emails Group (TEG)
Study: 24586897
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment Group (TG)
Study: 24586897
Drug: Delayed-Treatment Waitlist
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-Treatment Waitlist Control Group (Control)
Study: 20231532
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (5 mg folic acid, 50 microg vitamin B(12), 20 mg vitamin B(6))
Study: 20231532
Drug: Placebo (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.2 mg folic acid, 4 microg vitamin B(12), 1.0 mg vitamin B(6))
Study: 17430744
Drug: Natural laxative
Normalized name: Natural Laxative
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural laxative mixture (Beverley-Travis), 2 tablespoons twice a day for 4 weeks
Study: 17430744
Drug: Prescribed laxatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed laxatives (control group)
Study: 17430744
Drug: Natural laxative
Normalized name: Natural Laxative
DrugBank: Sennosides (DB11365)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural laxative mixture
Study: 11932294
Drug: T enanthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate (TE) 250 mg/wk im plus ethinylestradiol (EE2) 0.1 mg/d orally for 5.8 weeks
Study: 7612363
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine 50 mg initially, followed by 50 mg every 6 hours
Study: 7612363
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole 80 mg bolus initially, followed by 40 mg every 8 hours for 48 hours, then 40 mg every 12 hours until discharge
Study: 2371367
Drug: Sodium amytal
Normalized name: amobarbital sodium Injection [Amytal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium amytal (250 mg)
Study: 889069
Drug: Naloxone (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (high doses)
Study: 10963811
Drug: Birch-pollen immunotherapy
Normalized name: cherry birch pollen extract
DrugBank: Betula lenta pollen (DB10352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch-pollen immunotherapy (IT)
Study: 11776511
Drug: Hysteroscopic tubal
Normalized name: sodium thiosalicylate Injectable Solution [Tusal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 3 cm
Study: 11776511
Drug: Hysteroscopic tubal
Normalized name: sodium thiosalicylate Injectable Solution [Tusal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic tubal embryo transfer (h-TEST) using a catheter tapering at the distal 5 cm
Study: 9128316
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg taken late in the evening, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Study: 9128316
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg taken before breakfast, coupled with clarithromycin 250 mg b.i.d. and metronidazole 500 mg b.i.d. for the first 2 weeks.
Study: 1088951
Drug: Haloperidol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1.0 mg, intramuscular injection)
Study: 21464195
Drug: 2009 pandemic
Normalized name: Influenza A virus H1 2009 pandemic Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria) administered in 2 doses (dose 1 at enrollment and dose 2 after 4 weeks)
Study: 21464195
Drug: 2009 pandemic
Normalized name: Influenza A virus H1 2009 pandemic Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine (Focetria)
Study: 19542766
Drug: Long-term intake
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intake of 'benifuuki' green tea (34 mg O-methylated catechin per day for 1.5 months before pollen exposure)
Study: 16731323
Drug: Tramadol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (20 mg bolus, n = 13)
Study: 9656405
Drug: Ofloxacin containing
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin containing combined drug regimens
Study: 3168500
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antimicrobial agents (tobramycin, amphotericin B, polymyxin E) in addition to parenteral antibiotics
Study: 3168500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nonabsorbable antimicrobial agents)
Study: 3168500
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antimicrobial agents
Study: 21592480
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg/day for 4 weeks
Study: 14582689
Drug: Monochromatic pulsating
Normalized name: ABG Pulsator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic pulsating light treatment
Study: 11078237
Drug: Fluvastatin 20
Normalized name: fluvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 20 mg plus Fenofibrate 200 mg
Study: 11078237
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg plus Fenofibrate 200 mg
Study: 29381726
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (NVM group)
Study: 26771282
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing forskolin, homotaurine, carnosine, folic acid, vitamins B1, B2, B6, and magnesium, 2 tablets per day for 12 months.
Study: 26771282
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (not specified in detail).
Study: 24631567
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tDCS and MP
Study: 22271411
Drug: Colesevelam 1.875
Normalized name: colesevelam 1.875 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 1.875 g b.i.d. for 14 days
Study: 20306005
Drug: Intensive vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vascular care (4-monthly visits to a practice nurse monitoring cardiovascular risk factors)
Study: 18925641
Drug: Combination HBIG
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination HBIG plus lamivudine
Study: 18925641
Drug: Combination adefovir/lamivudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination adefovir/lamivudine prophylaxis
Study: 11863090
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus carboplatin (PC) - P 175 mg/m2 and C at AUC = 7, intravenous infusion on day 1
Study: 11863090
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus gemcitabine (PG) - P 175 mg/m2 on day 1 and G 1000 mg/m2 on days 1 and 8, every 3 weeks
Study: 7572513
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml gadopentetate dimeglumine
Study: 7572513
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml gadopentetate dimeglumine
Study: 7572513
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml gadopentetate dimeglumine
Study: 7011019
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily applications of a povidone-iodine solution and ointment
Study: 7011019
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily meatal cleansing with a nonantiseptic solution of green soap and water
Study: 7011019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment) for povidone-iodine